Avidity Partners 13F holdings, Q3 2021
Holdings as of September 30, 2021 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 103 US equity positions worth $3.9bn in its Q3 2021 13F filing. The largest position was MIRATI THERAPEUTICS INC at 4.8% of the reported book, followed by ARVN and ABBV. Against the Q2 2021 filing, it opened 12 new positions, added to 29 and reduced 9 among the top 50 holdings.
What did Avidity Partners own in Q3 2021? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2021 |
|---|---|---|---|---|---|---|---|
| 1 | MIRATI THERAPEUTICS INC | 4.8% | $187.9m | 1,062,400 | 41% | added | |
| 2 | ARVN ARVINAS INC | Healthcare | 4.7% | $183.6m | 2,234,700 | 21% | added |
| 3 | ABBV ABBVIE INC | Healthcare | 4.4% | $174.0m | 1,613,200 | 9% | added |
| 4 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 4.3% | $168.0m | 926,400 | -2% | reduced |
| 5 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 4.2% | $166.2m | 2,493,800 | 15% | added |
| 6 | AVTR AVANTOR INC | Healthcare | 3.4% | $132.8m | 3,247,700 | 2% | added |
| 7 | BIOHAVEN PHARMACTL HLDG CO L | 3.3% | $129.8m | 934,200 | 6% | added | |
| 8 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.3% | $92.2m | 4,823,400 | 5% | added |
| 9 | REGN REGENERON PHARMACEUTICALS | Healthcare | 2.3% | $92.2m | 152,300 | – | new |
| 10 | SEAGEN INC | 2.3% | $91.2m | 537,000 | -16% | reduced | |
| 11 | HORIZON THERAPEUTICS PUB L | 2.3% | $90.5m | 826,000 | 45% | added | |
| 12 | 2655787D BLUEPRINT MEDICINES CORP | 2.2% | $85.5m | 832,000 | 48% | added | |
| 13 | AZN ASTRAZENECA PLC | Healthcare | 2.2% | $84.8m | 1,412,000 | – | new |
| 14 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.1% | $81.4m | 848,900 | 25% | added |
| 15 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.1% | $80.6m | 427,000 | 119% | added |
| 16 | LLY LILLY ELI & CO | Healthcare | 1.9% | $76.2m | 330,000 | -42% | reduced |
| 17 | NUVB NUVATION BIO INC | Healthcare | 1.8% | $72.2m | 7,263,488 | 4% | added |
| 18 | NTRA NATERA INC | Healthcare | 1.8% | $71.2m | 638,700 | 46% | added |
| 19 | HO1 HOLOGIC INC | 1.8% | $69.8m | 945,400 | -22% | reduced | |
| 20 | BAX BAXTER INTL INC | Healthcare | 1.8% | $69.3m | 862,000 | – | new |
| 21 | ARENA PHARMACEUTICALS INC | 1.7% | $67.8m | 1,139,000 | 21% | added | |
| 22 | IVERIC BIO INC | 1.7% | $66.6m | 4,100,000 | 193% | added | |
| 23 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 1.7% | $64.8m | 351,000 | 48% | added |
| 24 | STVN STEVANATO GROUP S P A | 1.6% | $64.3m | 2,541,893 | – | new | |
| 25 | SHC SOTERA HEALTH CO | Healthcare | 1.6% | $62.2m | 2,378,000 | 25% | added |
| 26 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.6% | $62.1m | 2,437,000 | 18% | added |
| 27 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 1.5% | $59.1m | 2,474,067 | – | new |
| 28 | CATALENT INC | 1.4% | $53.0m | 398,000 | -26% | reduced | |
| 29 | 2JQ GRITSTONE BIO INC | 1.2% | $48.1m | 4,457,831 | 110% | added | |
| 30 | LEGN LEGEND BIOTECH CORP | Healthcare | 1.2% | $45.2m | 894,000 | 43% | added |
| 31 | ORTHO CLINICAL DIAGNOSTICS H | 1.1% | $44.3m | 2,398,000 | – | new | |
| 32 | PFE PFIZER INC | Healthcare | 1.1% | $44.2m | 1,026,800 | – | new |
| 33 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.1% | $42.1m | 673,700 | 548% | added |
| 34 | STTK SHATTUCK LABS INC | Healthcare | 1.1% | $41.3m | 2,025,000 | 4% | added |
| 35 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.0% | $41.0m | 455,000 | – | new |
| 36 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 1.0% | $40.6m | 1,095,600 | 82% | added |
| 37 | AVIDITY BIOSCIENCES INC | 1.0% | $40.5m | 1,645,000 | – | new | |
| 38 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.9% | $36.1m | 1,462,200 | – | new |
| 39 | INSM INSMED INC | Healthcare | 0.9% | $35.6m | 1,292,000 | 12% | added |
| 40 | EXK EXACT SCIENCES CORP | Basic Materials | 0.9% | $35.2m | 369,000 | -37% | reduced |
| 41 | CMPS COMPASS PATHWAYS PLC | Healthcare | 0.9% | $34.7m | 1,162,000 | 16% | added |
| 42 | ATEC ALPHATEC HLDGS INC | Healthcare | 0.9% | $34.0m | 2,786,000 | 6% | added |
| 43 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.9% | $33.7m | 251,000 | -34% | reduced |
| 44 | NBP I MAB | Healthcare | 0.8% | $32.9m | 454,000 | -38% | reduced |
| 45 | SEASPINE HLDGS CORP | 0.8% | $30.6m | 1,943,000 | 27% | added | |
| 46 | BELLUS HEALTH INC NEW | 0.8% | $30.3m | 4,942,000 | 16% | added | |
| 47 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 0.8% | $30.2m | 514,500 | – | new |
| 48 | CYTEIR THERAPEUTICS INC | 0.8% | $29.5m | 1,683,441 | -7% | reduced | |
| 49 | ALT ALTIMMUNE INC | Healthcare | 0.6% | $24.5m | 2,167,900 | – | new |
| 50 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 0.6% | $22.4m | 515,000 | 218% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.